Tumor neoantigEn SeLection Alliance (TESLA)
A global research alliance of 30 public and private groups working to advance the development of more effective personalized cancer treatments
The search for unique cancer markers known as tumor neoantigens has become a robust area of oncology research. Along with other advances in technology, neoantigens are reviving hope that personalized cancer vaccines tailored to a patient’s tumor can quell cancer for an extended period of time, and do so with fewer side effects.
To accelerate discoveries in this area, the Parker Institute for Cancer Immunotherapy and the Cancer Research Institute (CRI) launched the Tumor Neoantigen Selection Alliance in fall of 2016. This global bioinformatics collaborative includes scientists from more than 35 of the leading neoantigen research groups in academia, nonprofit and industry. Sage Bionetworks is managing the bioinformatics and data analysis.
The goal is to find the most effective ways to use algorithms for predicting which cancer neoantigens encoded in DNA and RNA can be recognized by and stimulate an immune response. Better predictive algorithms for finding neoantigens could allow scientists to create more cancer immunotherapy treatments tailored to each patient.
Initially, the project will focus on advanced melanoma, colorectal cancer and non-small cell lung cancer.
More Scientific Coordination Projects
Multi-Consortia Coordinating (MC2) Center
Sage Bionetworks leads the Multi-Consortia Coordinating (MC2) Center for six research consortia from the NIH/NCI Division of Cancer Biology. The MC2 Center aims to catalyze...Learn More
The Gray Foundation
The Gray Foundation "Team Science" philanthropic initiative funds a network of researchers to study new approaches for the early detection, diagnosis, and therapy of BRCA-related...Learn More
The First 1000 Days 1kD
The 1kD program is an international effort to better understand executive development in toddlers up to 1000 days old.Learn More